{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T08:04:42Z","timestamp":1784189082690,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40273-026-01615-2","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T16:34:45Z","timestamp":1776357285000},"page":"949-962","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Balancing Innovation and Access: Insights from AIM\u2019s Fair Pricing Model and Its Current and Future Applications"],"prefix":"10.1007","volume":"44","author":[{"given":"Jocelijn","family":"Stokx","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Hendrickx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00e4rt","family":"Veliste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Brouns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Scheffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goentje-Gesine","family":"Schoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Slapsak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Macken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kanga-Tona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1239-9867","authenticated-orcid":false,"given":"Sahar","family":"Barjesteh van Waalwijk van Doorn-Kh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"issue":"21","key":"1615_CR1","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1001\/jama.2022.5542","volume":"327","author":"BN Rome","year":"2022","unstructured":"Rome BN, Egilman AC, Kesselheim AS. Trends in prescription drug launch prices, 2008\u20132021. JAMA. 2022;327(21):2145\u20137. https:\/\/doi.org\/10.1001\/jama.2022.5542.","journal-title":"JAMA"},{"key":"1615_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-011965","volume":"7","author":"A Hill","year":"2017","unstructured":"Hill A, Redd C, Gotham D, Erbacher I, Meldrum J, Harada R. Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis. BMJ Open. 2017;7:e011965. https:\/\/doi.org\/10.1136\/bmjopen-2016-011965.","journal-title":"BMJ Open"},{"issue":"6","key":"1615_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0338-x","volume":"10","author":"V Rajkumar S","year":"2020","unstructured":"Rajkumar S V. The high cost of prescription drugs: causes and solutions. Blood Cancer J. 2020;10(6):71. https:\/\/doi.org\/10.1038\/s41408-020-0338-x.","journal-title":"Blood Cancer J"},{"key":"1615_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4530","volume":"359","author":"C Davis","year":"2017","unstructured":"Davis C, Naci H, Gurpinar E, Poplavska E, Pinto A, Aggarwal A. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. BMJ (Clinical research ed). 2017;359:j4530. https:\/\/doi.org\/10.1136\/bmj.j4530.","journal-title":"BMJ (Clinical research ed.)"},{"key":"1615_CR5","doi-asserted-by":"publisher","DOI":"10.57598\/R343C","author":"M Neyt","year":"2021","unstructured":"Neyt M, Devos C, Thiry N, Silversmit G, De Gendt C, Van Damme N, et al. Do innovative medicines against cancer always have a real added value? KCE Rep. 2021. https:\/\/doi.org\/10.57598\/R343C.","journal-title":"KCE Rep."},{"key":"1615_CR6","unstructured":"Joint Clinical Assessments [Internet]. [Cited 2025 Feb 3]. Joint Clinical Assessments\u2014Public Health\u2014European Commission."},{"key":"1615_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40273-023-01325-z","volume":"42","author":"M Paulden","year":"2024","unstructured":"Paulden M. A framework for the fair pricing of medicines. Pharmacoeconomics. 2024;42:145\u201364. https:\/\/doi.org\/10.1007\/s40273-023-01325-z.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"1615_CR8","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1080\/14737167.2021.1884546","volume":"21","author":"B Godman","year":"2021","unstructured":"Godman B, Hill A, Simoens S, Selke G, Selke Krulichov\u00e1 I, Zampirolli Dias C, et al. Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. Expert Rev Pharmacoecon Outcomes Res. 2021;21(4):527\u201340. https:\/\/doi.org\/10.1080\/14737167.2021.1884546.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1615_CR9","doi-asserted-by":"publisher","DOI":"10.1787\/6e5e4c0f-en","author":"M Wenzl","year":"2019","unstructured":"Wenzl M, Chapman S. Performance-based managed entry agreements for new medicines in OECD countries and EU member states: How they work and possible improvements going forward. OECD Health Working Pap. 2019. https:\/\/doi.org\/10.1787\/6e5e4c0f-en.","journal-title":"OECD Health Working Pap."},{"issue":"1","key":"1615_CR10","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2017.1369817","volume":"5","author":"KE Young","year":"2017","unstructured":"Young KE, Soussi I, Toumi M. The perverse impact of external reference pricing (ERP): a comparison of orphan drugs affordability in 12 European countries. A call for policy change. J Mark Access Health Policy. 2017;5(1):1369817. https:\/\/doi.org\/10.1080\/20016689.2017.1369817.","journal-title":"J Mark Access Health Policy"},{"issue":"12","key":"1615_CR11","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s40273-017-0559-4","volume":"35","author":"A Ferrario","year":"2017","unstructured":"Ferrario A, Ar\u0101ja D, Bochenek T, \u010cati\u0107 T, Dank\u00f3 D, Dimitrova M, et al. The implementation of managed entry agreements in Central and Eastern Europe: findings and implications. Pharmacoeconomics. 2017;35(12):1271\u201385. https:\/\/doi.org\/10.1007\/s40273-017-0559-4.","journal-title":"Pharmacoeconomics"},{"key":"1615_CR12","unstructured":"Cross-country collaborations to improve access to medicines and vaccines in the WHO European Region. Copenhagen: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"1615_CR13","unstructured":"BeNeLuxa initiative [Internet]. [Cited 2026 Feb 3]. Beneluxa initiative | BeNeLuxA"},{"key":"1615_CR14","unstructured":"AIM. AIM\u2019s fair pricing model: accompanying paper to the fair pricing calculator. 2021. https:\/\/www.aim-mutual.org\/wp-content\/uploads\/2021\/06\/AIMs-fair-pricing-model-Accompanying-paper-to-the-fair-pricing-calculator_June2021.pdf. Accessed 8 Aug 2025."},{"key":"1615_CR15","unstructured":"Medicines: Fair pricing forum [Internet]. [Cited 2025 Sept 8]. Medicines: Fair pricing forum."},{"issue":"5","key":"1615_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002032","volume":"13","author":"S Iyengar","year":"2016","unstructured":"Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, et al. Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis. PLoS Med. 2016;13(5):e1002032. https:\/\/doi.org\/10.1371\/journal.pmed.1002032.","journal-title":"PLoS Med"},{"key":"1615_CR17","unstructured":"European Fair price calculator for medicines. [Internet]. [Cited 2025 Aug 8]. https:\/\/fairpricingcalculator.eu\/. Accessed 8 Aug 2025."},{"key":"1615_CR18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","volume":"47","author":"JA DiMasi","year":"2016","unstructured":"DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20\u201333. https:\/\/doi.org\/10.1016\/j.jhealeco.2016.01.012.","journal-title":"J Health Econ"},{"issue":"9","key":"1615_CR19","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2020.1166","volume":"323","author":"OJ Wouters","year":"2020","unstructured":"Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009\u20132018. JAMA. 2020;323(9):844\u201353. https:\/\/doi.org\/10.1001\/jama.2020.1166.","journal-title":"JAMA"},{"issue":"7","key":"1615_CR20","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41571-018-0027-x","volume":"15","author":"CA Uyl-de Groot","year":"2018","unstructured":"Uyl-de Groot CA, L\u00f6wenberg B. Sustainability and affordability of cancer drugs: a novel pricing model. Nat Rev Clin Oncol. 2018;15(7):405\u20136. https:\/\/doi.org\/10.1038\/s41571-018-0027-x.","journal-title":"Nat Rev Clin Oncol"},{"key":"1615_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009586","volume":"6","author":"A Hill","year":"2016","unstructured":"Hill A, Gotham D, Fortunak J, Meldrum J, Erbacher I, Martin M, et al. Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment. BMJ Open. 2016;6:e009586. https:\/\/doi.org\/10.1136\/bmjopen-2015-009586.","journal-title":"BMJ Open"},{"issue":"3","key":"1615_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jve.2020.06.001","volume":"6","author":"MJ Barber","year":"2020","unstructured":"Barber MJ, Gotham D, Khwairakpam G, Hill A. Price of a Hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries. J Virus Erad. 2020;6(3):100001. https:\/\/doi.org\/10.1016\/j.jve.2020.06.001.","journal-title":"J Virus Erad"},{"key":"1615_CR23","unstructured":"Properly unhealthy: Big Pharma rakes in 40\u201390% profit margins on cancer medicines. Report. 2022. 2022_PublicEye_ProperlyUnhealthy_Report.pdf."},{"issue":"5","key":"1615_CR24","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.2139\/ssrn.4068270","volume":"31","author":"J Levi","year":"2023","unstructured":"Levi J, Wang J, Venter F, Hill A. Estimated costs of production compared with national prices, for drugs to treat clinical obesity. Obesity (Silver Spring, Md). 2023;31(5):1270\u20139. https:\/\/doi.org\/10.2139\/ssrn.4068270.","journal-title":"Obesity (Silver Spring, Md.)"},{"issue":"Suppl 6(Suppl 6","key":"1615_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-S6-S5","volume":"14","author":"M Phelan","year":"2014","unstructured":"Phelan M, Cook C. A treatment revolution for those who can afford it? Hepatitis C treatment: new medications, profits and patients. BMC Infect Dis. 2014;14(Suppl 6(Suppl 6)):S5. https:\/\/doi.org\/10.1186\/1471-2334-14-S6-S5.","journal-title":"BMC Infect Dis"},{"key":"1615_CR26","unstructured":"Summary of product Characteristic of Ibrance. Ibrance, INN - palbociclib"},{"key":"1615_CR27","unstructured":"Muth L, Neitemeier S, Dammann D, Steimle T, Glaeske G. AIM fair price calculator for patent-protected medicines: an approach to calculating fairer pharmaceutical prices in the EU and beyond. 2021. https:\/\/www.aim-mutual.org\/wp-content\/uploads\/2021\/10\/TK_AIM-Fair-Pricing-Calculator-EN_Rev.pdf. Accessed 11 Aug 2025."},{"key":"1615_CR28","unstructured":"Hendrickx A, Vos B, Vrancken J, Bourda A, Demyttenaere B. What would be the impact of fair prices for medicines in Belgium? Research based on 7 cases. 2022. https:\/\/www.aim-mutual.org\/wp-content\/uploads\/2023\/11\/Solidaris-Impact-Fair-price-in-Belgium-01-2023-def.pdf. Accessed 11 Aug 2025."},{"issue":"1","key":"1615_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12962-020-00223-x8","volume":"18","author":"M Berdud","year":"2020","unstructured":"Berdud M, Drummond M, Towse A. Establishing a reasonable price for orphan drug. Cost Eff Resour Alloc. 2020;18(1):1\u201318. https:\/\/doi.org\/10.1186\/s12962-020-00223-x8.","journal-title":"Cost Eff Resour Alloc"},{"key":"1615_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i1284","volume":"352","author":"N Ghinea","year":"2016","unstructured":"Ghinea N, Lipworth W, Kerridge I. Propaganda or the cost of innovation? Challenging the high price of new drugs. BMJ. 2016;352:i1284. https:\/\/doi.org\/10.1136\/bmj.i1284.","journal-title":"BMJ"},{"issue":"4","key":"1615_CR31","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.cell.2017.01.034","volume":"168","author":"P Workman","year":"2017","unstructured":"Workman P, Draetta GF, Schellens JHM, Bernards R. How much longer will we put up with $100,000 cancer drugs? Cell. 2017;168(4):579\u201383. https:\/\/doi.org\/10.1016\/j.cell.2017.01.034.","journal-title":"Cell"},{"issue":"11","key":"1615_CR32","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s40273-021-01065-y","volume":"39","author":"M Schlander","year":"2021","unstructured":"Schlander M, Hernandez-Villafuerte K, Cheng CY, Mestre-Ferrandiz J, Baumann M. How much does it cost to research and develop a new drug? A systematic review and assessment. Pharmacoeconomics. 2021;39(11):1243\u201369. https:\/\/doi.org\/10.1007\/s40273-021-01065-y.","journal-title":"Pharmacoeconomics"},{"key":"1615_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f398","volume":"346","author":"PC G\u00f8tzsche","year":"2013","unstructured":"G\u00f8tzsche PC. Developing a new drug costs less than $100m, not $900m. BMJ. 2013;346:f398. https:\/\/doi.org\/10.1136\/bmj.f398.","journal-title":"BMJ"},{"key":"1615_CR34","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2024.ed131","volume":"18","author":"R Sullivan","year":"2024","unstructured":"Sullivan R. Cancer medicines: a private vice for public benefit? Ecancermedicalscience. 2024;18:ed131. https:\/\/doi.org\/10.3332\/ecancer.2024.ed131.","journal-title":"Ecancermedicalscience"},{"key":"1615_CR35","unstructured":"Zorgverzekeraars Nederland. Dutch insurers apply AIM\u2019s fair pricing calculator by default when negotiating drug prices with companies [internet]. [Cited 2025 Jun 10]. https:\/\/www.aim-mutual.org. Accessed 10 Jun 2025."},{"issue":"7","key":"1615_CR36","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.jval.2021.02.004","volume":"24","author":"S Van den Berg","year":"2021","unstructured":"Van den Berg S, van der Wel V, de Visser SJ, Stunnenberg BC, Timmers L, van der Ree MH, et al. Cost-based price calculation of mexiletine for nondystrophic myotonia. Value Health. 2021;24(7):925\u20139. https:\/\/doi.org\/10.1016\/j.jval.2021.02.004.","journal-title":"Value Health"},{"key":"1615_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03446-w","volume":"19","author":"N Rosenberg","year":"2024","unstructured":"Rosenberg N, Manders E, van den Berg S, Deesker LJ, Garrelfs SF, de Visser SJ, et al. Application of four pricing models for orphan medicines: a case study for lumasiran. Orphanet J Rare Dis. 2024;19:485. https:\/\/doi.org\/10.1186\/s13023-024-03446-w.","journal-title":"Orphanet J Rare Dis"},{"key":"1615_CR38","unstructured":"ASCERTAIN. Improving access to innovative health technologies. [Internet]. [Cited 2025 Jun 13]. https:\/\/access2meds.eu\/. Accessed 13 Jun 2025."},{"key":"1615_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.873556","volume":"13","author":"A Pisana","year":"2022","unstructured":"Pisana A, Wettermark B, Kurdi A, Tubic B, Pontes C, Zara C, et al. Challenges and opportunities with routinely collected data on the utilization of cancer medicines. Perspectives from health authority personnel across 18 European countries. Front Pharmacol. 2022;13:873556. https:\/\/doi.org\/10.3389\/fphar.2022.873556.","journal-title":"Front Pharmacol"},{"key":"1615_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4726","volume":"368","author":"S Moon","year":"2020","unstructured":"Moon S, Mariat S, Kamae I, Pedersen HB. Defining the concept of fair pricing for medicines. BMJ. 2020;368:l4726. https:\/\/doi.org\/10.1136\/bmj.l4726.","journal-title":"BMJ"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01615-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-026-01615-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01615-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T07:20:44Z","timestamp":1784186444000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-026-01615-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1615"],"URL":"https:\/\/doi.org\/10.1007\/s40273-026-01615-2","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: to correct the alignment of entries in tables.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study does not involve human subjects, and under 45 CFR \u00a746.102(f), was not submitted for institutional review board approval and did not require informed consent.","order":1,"name":"Ethics","label":"Ethics committee approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sahar Barjesteh van Waalwijk van Doorn-Khosrovani received research funding from Horizon Europe Cancer Mission, EC grant agreement no. 101104269 (PRIME-ROSE) and Joint Action for Personalised Cancer Medicine (JA-PCM), financed by EU4Health (grant no. 101233450). All authors have no financial conflicts of interest related to this manuscript.","order":2,"name":"Ethics","label":"Conflict of interest statements","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors were involved in the selection of medicines and study design. A representative from each country provided the relevant country-specific data. JS and AH curated the data, conducted the analysis, and wrote the first draft of the manuscript. TKT assisted with the analysis and coordinated the study across countries. All authors reviewed and approved the final version.","order":3,"name":"Ethics","label":"Authors contribution","group":{"name":"EthicsHeading","label":"Declarations"}}]}}